NCT02095158View on ClinicalTrials.gov

A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea

PHASE3CompletedINTERVENTIONAL
Enrollment

440

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

September 30, 2015

Conditions
ErythemaRosacea
Interventions
DRUG

Oxymetazoline HCL Cream 1.0%

Oxymetazoline HCL Cream 1.0% applied to the face once daily for 52 weeks.

Trial Locations (1)

Unknown

Portland

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY